Compare ST & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ST | PTCT |
|---|---|---|
| Founded | 1916 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.7B |
| IPO Year | 2009 | 2006 |
| Metric | ST | PTCT |
|---|---|---|
| Price | $49.55 | $77.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $42.91 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,704,500,000.00 | $264,734,000.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $4.51 | $17.70 |
| P/E Ratio | $85.17 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $27.85 | $43.18 |
| 52 Week High | $53.89 | $87.50 |
| Indicator | ST | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 62.03 |
| Support Level | $33.15 | $73.41 |
| Resistance Level | $53.89 | $79.67 |
| Average True Range (ATR) | 2.16 | 3.10 |
| MACD | -0.41 | 0.54 |
| Stochastic Oscillator | 41.87 | 85.53 |
Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.